ProfileGDS5678 / 1453705_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 68% 68% 67% 67% 70% 68% 68% 68% 68% 70% 68% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2414869
GSM967853U87-EV human glioblastoma xenograft - Control 24.1574768
GSM967854U87-EV human glioblastoma xenograft - Control 34.1580268
GSM967855U87-EV human glioblastoma xenograft - Control 44.1067867
GSM967856U87-EV human glioblastoma xenograft - Control 54.0428367
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3062270
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2209668
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1493268
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.144968
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1494268
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3025870
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1294468
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.155168
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1603868